28146402|t|A Multicenter Study of Early Anti-inflammatory Treatment in Patients With Acute Anterior Cruciate Ligament Tear
28146402|a|It is increasingly recognized that biochemical abnormalities of the joint precede radiographic abnormalities of posttraumatic osteoarthritis (PTOA) by as much as decades. A growing body of evidence strongly suggests that the progression from anterior cruciate ligament (ACL) injury to PTOA is multifactorial, involving the interplay between biomechanical disturbances and biochemical homeostasis of articular cartilage. The purposes of this randomized study using an acute ACL injury model were to (1) evaluate the natural progression of inflammatory and chondrodegenerative biomarkers, (2) evaluate the relationship between subjective reports of pain and inflammatory and chondrodegenerative biomarkers, and (3) determine if postinjury arthrocentesis and corticosteroid injection offer the ability to alter this biochemical cascade. Randomized controlled trial; Level of evidence, 2. A total of 49 patients were randomized to 4 groups: group 1 (corticosteroid at 4 days after ACL injury, placebo injection of saline at 2 weeks), group 2 (placebo at 4 days after ACL injury, corticosteroid at 2 weeks), group 3 (corticosteroid at both time intervals), or a placebo group (saline injections at both time intervals). Patient-reported outcome measures and synovial biomarkers were collected at approximately 4 days, 11 days, and 5 weeks after injury. The change between the time points was assessed for all variables using Wilcoxon tests, and the relationship between changes in outcome scores and biomarkers were assessed by calculating Spearman ρ. Outcomes and biomarkers were also compared between the 4 groups using Kruskal-Wallis tests. No adverse events or infections were observed in any study patients. With the exception of matrix metalloproteinase 1 (MMP-1) and tumor necrosis factor-inducible gene 6 (TSG-6), chondrodegenerative markers worsened over the first 5 weeks while all patient-reported outcomes improved during this time, regardless of treatment group. Patient-reported outcomes did not differ between patients receiving corticosteroid injections and the placebo group. However, increases in C-telopeptide of type II collagen (CTX-II), associated with collagen type II breakdown, were significantly greater in the placebo group (1.32 ± 1.10 ng/mL) than in either of the groups that received the corticosteroid injection within the first several days after injury (group 1: 0.23 ± 0.27 ng/mL [P = .01]; group 3: 0.19 ± 0.34 ng/mL [P = .01]). PTOA begins at the time of injury and results early on in dramatic matrix changes in the knee. However, it is encouraging that early intervention with an anti-inflammatory agent was able to affect biomarkers of chondral degeneration. Should early intervention lead to meaningful changes in either the onset or severity of symptomatic PTOA, the current treatment paradigm for patients with ACL injury may have to be restructured to include early aspiration and intra-articular intervention. ClinicalTrials.gov identifier: NCT01692756.
28146402	2	19	Multicenter Study	T062	C1096776
28146402	23	28	Early	T079	C1279919
28146402	29	46	Anti-inflammatory	T121	C0003209
28146402	47	56	Treatment	T169	C0039798
28146402	60	68	Patients	T101	C0030705
28146402	74	111	Acute Anterior Cruciate Ligament Tear	T037	C2584975
28146402	147	158	biochemical	T169	C0205474
28146402	159	172	abnormalities	T020	C0221430
28146402	180	185	joint	T030	C0022417
28146402	194	220	radiographic abnormalities	T033	C1704258
28146402	224	252	posttraumatic osteoarthritis	T046	C2894027
28146402	254	258	PTOA	T046	C2894027
28146402	337	348	progression	T046	C0242656
28146402	354	393	anterior cruciate ligament (ACL) injury	T037	C2584975
28146402	397	401	PTOA	T046	C2894027
28146402	405	419	multifactorial	T033	C1837655
28146402	453	479	biomechanical disturbances	T080	C2699787
28146402	484	495	biochemical	T169	C0205474
28146402	496	507	homeostasis	T038	C0019868
28146402	511	530	articular cartilage	T024	C0007303
28146402	553	569	randomized study	T062	C0242481
28146402	579	595	acute ACL injury	T037	C2584975
28146402	596	601	model	T075	C0026336
28146402	627	634	natural	T169	C0205296
28146402	635	646	progression	T169	C0449258
28146402	650	662	inflammatory	T201	C0005516
28146402	667	697	chondrodegenerative biomarkers	T201	C0005516
28146402	716	728	relationship	T080	C0439849
28146402	737	755	subjective reports	T170	C0684224
28146402	759	763	pain	T184	C0030193
28146402	768	780	inflammatory	T201	C0005516
28146402	785	815	chondrodegenerative biomarkers	T201	C0005516
28146402	838	863	postinjury arthrocentesis	T061	C0204854
28146402	868	882	corticosteroid	T121	C3536709
28146402	883	892	injection	T061	C0021485
28146402	925	944	biochemical cascade	T044	C1704259
28146402	946	973	Randomized controlled trial	T062	C0206035
28146402	975	980	Level	T080	C0441889
28146402	984	992	evidence	T078	C3887511
28146402	1011	1019	patients	T101	C0030705
28146402	1025	1035	randomized	T062	C0034656
28146402	1041	1047	groups	T078	C0441833
28146402	1049	1056	group 1	T170	C0441861
28146402	1058	1072	corticosteroid	T121	C3536709
28146402	1078	1082	days	T079	C0439228
28146402	1089	1099	ACL injury	T037	C2584975
28146402	1101	1108	placebo	T122	C1696465
28146402	1109	1118	injection	T061	C1533685
28146402	1122	1128	saline	T167	C0036082
28146402	1134	1139	weeks	T079	C0439230
28146402	1142	1149	group 2	T170	C0441865
28146402	1151	1158	placebo	T122	C1696465
28146402	1164	1168	days	T079	C0439228
28146402	1175	1185	ACL injury	T037	C2584975
28146402	1187	1201	corticosteroid	T121	C3536709
28146402	1207	1212	weeks	T079	C0439230
28146402	1215	1222	group 3	T170	C0441869
28146402	1224	1238	corticosteroid	T121	C3536709
28146402	1247	1261	time intervals	T079	C0872291
28146402	1269	1276	placebo	T122	C1696465
28146402	1277	1282	group	T078	C0441833
28146402	1284	1290	saline	T167	C0036082
28146402	1291	1301	injections	T061	C1533685
28146402	1310	1324	time intervals	T079	C0872291
28146402	1327	1360	Patient-reported outcome measures	T058	C4277735
28146402	1365	1373	synovial	T023	C1550315
28146402	1374	1384	biomarkers	T201	C0005516
28146402	1419	1423	days	T079	C0439228
28146402	1428	1432	days	T079	C0439228
28146402	1440	1445	weeks	T079	C0439230
28146402	1452	1458	injury	T037	C3263723
28146402	1464	1470	change	T169	C0392747
28146402	1483	1494	time points	T079	C0439547
28146402	1499	1507	assessed	T052	C1516048
28146402	1516	1525	variables	T080	C0439828
28146402	1532	1546	Wilcoxon tests	T170	C0871608
28146402	1556	1568	relationship	T080	C0439849
28146402	1577	1584	changes	T169	C0392747
28146402	1588	1602	outcome scores	T033	C4274403
28146402	1607	1617	biomarkers	T201	C0005516
28146402	1623	1631	assessed	T052	C1516048
28146402	1647	1657	Spearman ρ	T062,T170	C0872006
28146402	1659	1667	Outcomes	T080	C0085415
28146402	1672	1682	biomarkers	T201	C0005516
28146402	1716	1722	groups	T078	C0441833
28146402	1729	1749	Kruskal-Wallis tests	T170	C1708614
28146402	1751	1768	No adverse events	T033	C1963761
28146402	1772	1782	infections	T046	C3714514
28146402	1804	1809	study	T062	C2603343
28146402	1810	1818	patients	T101	C0030705
28146402	1842	1868	matrix metalloproteinase 1	T116,T126	C0127082
28146402	1870	1875	MMP-1	T116,T126	C0127082
28146402	1881	1919	tumor necrosis factor-inducible gene 6	T116,T123	C0033684
28146402	1921	1926	TSG-6	T116,T123	C0033684
28146402	1929	1956	chondrodegenerative markers	T201	C0005516
28146402	1983	1988	weeks	T079	C0439230
28146402	1999	2024	patient-reported outcomes	T170	C2987124
28146402	2046	2050	time	T079	C0040223
28146402	2066	2075	treatment	T169	C0039798
28146402	2076	2081	group	T078	C0441833
28146402	2083	2108	Patient-reported outcomes	T170	C2987124
28146402	2132	2140	patients	T101	C0030705
28146402	2141	2150	receiving	T080	C1514756
28146402	2151	2165	corticosteroid	T121	C3536709
28146402	2166	2176	injections	T061	C0021485
28146402	2185	2192	placebo	T122	C1696465
28146402	2193	2198	group	T078	C0441833
28146402	2209	2218	increases	T169	C0442805
28146402	2222	2255	C-telopeptide of type II collagen	T116,T123	C3849640
28146402	2257	2263	CTX-II	T116,T123	C3849640
28146402	2266	2281	associated with	T080	C0332281
28146402	2282	2298	collagen type II	T116,T123	C0009331
28146402	2299	2308	breakdown	T044	C1157968
28146402	2344	2351	placebo	T122	C1696465
28146402	2352	2357	group	T078	C0441833
28146402	2400	2406	groups	T078	C0441833
28146402	2412	2420	received	T080	C1514756
28146402	2425	2439	corticosteroid	T121	C3536709
28146402	2440	2449	injection	T061	C0021485
28146402	2475	2479	days	T079	C0439228
28146402	2486	2492	injury	T037	C3263723
28146402	2494	2501	group 1	T170	C0441861
28146402	2532	2539	group 3	T170	C0441869
28146402	2571	2575	PTOA	T046	C2894027
28146402	2590	2594	time	T079	C0040223
28146402	2598	2604	injury	T037	C3263723
28146402	2617	2622	early	T079	C1279919
28146402	2638	2644	matrix	T024	C0005962
28146402	2645	2652	changes	T169	C0392747
28146402	2660	2664	knee	T023	C0022742
28146402	2698	2703	early	T079	C1279919
28146402	2704	2716	intervention	T061	C0184661
28146402	2725	2748	anti-inflammatory agent	T121	C0003209
28146402	2768	2778	biomarkers	T201	C0005516
28146402	2782	2803	chondral degeneration	T169	C1880269
28146402	2812	2817	early	T079	C1279919
28146402	2818	2830	intervention	T061	C0184661
28146402	2850	2857	changes	T169	C0392747
28146402	2872	2877	onset	T080	C0332162
28146402	2881	2889	severity	T080	C0439793
28146402	2893	2904	symptomatic	T169	C0231220
28146402	2905	2909	PTOA	T046	C2894027
28146402	2923	2932	treatment	T169	C0039798
28146402	2946	2954	patients	T101	C0030705
28146402	2960	2970	ACL injury	T037	C2584975
28146402	3010	3015	early	T079	C1279919
28146402	3016	3026	aspiration	T061	C0349707
28146402	3031	3046	intra-articular	T169	C1522204
28146402	3047	3059	intervention	T061	C0184661